Senior CNS/PNS Safety Scientist - NAMs & In Vitro Models

Eli Lilly and Company; Indianapolis (IN); On-site; USD 126,000 - 205,000; Full time

Benefits offered by this job

401(k) plan

Pension

Vacation benefits

Medical, dental, vision benefits

Flexible benefits

Life insurance

Time off benefits

Well-being programs

Job summary

Lilly is seeking a highly motivated scientist to join the NAMs/CIVMs pillar in Investigative Toxicology. You will design and apply advanced human-relevant in vitro CNS/PNS models to detect neural liabilities across CNS, PNS, and BBB, using iPSC-derived neurons, glia, co-cultures, organoids, DRG neurons, and BBB models.

You will investigate mechanistic liabilities such as excitotoxicity, neuroinflammation, and BBB disruption, integrating with in silico data to guide safety decisions.

Qualifications

• PhD in Neuroscience or closely related field.
• 2+ years postdoc/industry hands-on neural in vitro model experience.
• Senior level: 5+ years postdoc/industry independent contribution and leadership.

Responsibilities

• Develop, qualify, and apply human-relevant in vitro CNS/PNS models (neurons, glia, co-cultures, organoids, DRG, BBB).
• Investigate mechanistic CNS/PNS liabilities (excitotoxicity, neuroinflammation, mitochondrial dysfunction).
• Use MEA/FLIPR readouts for seizure potential and network activity; validate new assays and endpoints.

Skills

iPSC neurons

MEA/FLIPR assays

BBB models

neural organoids

neural toxicity

in vitro safety

Education

PhD in Neuroscience or closely related

2+ years postdoc/industry experience in neural in vitro models

Tools

iPSC cultureTechniques

Organoid culture

MEAs/FLIPR platforms

Job description

Lilly is seeking a highly motivated scientist to join the NAMs/CIVMs pillar in Investigative Toxicology. You will design and apply advanced human-relevant in vitro CNS/PNS models to detect neural liabilities across CNS, PNS, and BBB, using iPSC-derived neurons, glia, co-cultures, organoids, DRG neurons, and BBB models.

You will investigate mechanistic liabilities such as excitotoxicity, neuroinflammation, and BBB disruption, integrating with in silico data to guide safety decisions.